Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates to address large market opportunities, initially in ophthalmic conditions, where there are limited treatment alternatives. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Its lead product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of Demodex blepharitis.

Tarsus Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Life Science, Biopharma sector. The company focuses on Biotechnology and has secured $49.2B in funding across 84 round(s). With a team of 101-250 employees, Tarsus Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Debt - Tarsus Pharmaceuticals, raised $75.0M. Discover more about their projects, partnerships, and impact on our platform.